eric
10-18-2004, 05:06 AM
Parker Hughes scientists have
developed a new technology capable of preventing the development of breast
cancer in mice. The results from these research studies will be published in
two back-to-back papers in the November issue of the prestigious international
medical journal Arzneimittelforschung (Drug Research). The technology was
developed through the combined use of chemistry biology bioinformatics
pharmacology and mathematics.
In the studies Parker Hughes scientists found that a novel cytotoxic
nucleoside analog Compound 003 [3'-Azidothymidine 5' - [p-Methoxyphenyl
methoxyalaninyl phospate] was well tolerated in both mice and rats without
toxicity. Most notably Compound 003 prolonged cancer-free survival in
transgenic mice which otherwise invariably develop HER2 positive metastatic
breast cancer without any significant side effects and at dose levels much
lower than those found to be safe in animals.
developed a new technology capable of preventing the development of breast
cancer in mice. The results from these research studies will be published in
two back-to-back papers in the November issue of the prestigious international
medical journal Arzneimittelforschung (Drug Research). The technology was
developed through the combined use of chemistry biology bioinformatics
pharmacology and mathematics.
In the studies Parker Hughes scientists found that a novel cytotoxic
nucleoside analog Compound 003 [3'-Azidothymidine 5' - [p-Methoxyphenyl
methoxyalaninyl phospate] was well tolerated in both mice and rats without
toxicity. Most notably Compound 003 prolonged cancer-free survival in
transgenic mice which otherwise invariably develop HER2 positive metastatic
breast cancer without any significant side effects and at dose levels much
lower than those found to be safe in animals.